<p class="first" id="d26015596e148">A2B adenosine receptors are present in a wide
spectrum of tissues, especially on cells
of the immune system. Since these particular receptors have the lowest, of all adenosine
receptor subtypes, affinity for adenosine they are believed to play a special role
in immunological processes associated with elevated adenosine levels such as inflammation.
The aim of this preliminary study was to determine the potential anti-inflammatory
properties of compound PSB-603, a potent and selective adenosine A2B receptor antagonist,
in two different experimental models of local and systemic inflammation. In a model
of inflammation induced by local carrageenan administration paw edema was measured
using a pletysmometer. Additionally, levels of C-reactive protein (CRP), interleukin-6
(IL-6), tumor necrosis factor alpha (TNF-α) and reactive oxygen species (ROS) were
determined in the inflamed paw. Using the mouse model of peripheral inflammation induced
by intraperitoneal (ip) administration of zymosan A, the influence of the A2B antagonist
on the infiltration of neutrophils into the peritoneum and its effect on the plasma
levels of CRP, TNF-α, and IL-6 were investigated. The results showed that PSB-603
administered at a dose of 5 mg/kg b.w. ip significantly reduced inflammation in both
tested models. Particularly, it significantly decreased levels of the inflammatory
cytokines IL-6, TNF-α and of ROS in the inflamed paw and reduced inflammation of the
peritoneum by significantly decreasing the infiltration of leukocytes. Additionally,
in the latter model, no statistically significant difference was observed in the CRP
level between the control group without inflammation and the group which has been
treated with the PSB-603 compound. Thus, the results may indicate the anti-inflammatory
activity of adenosine A2B receptor antagonists in two different models of inflammation.
</p>